# VK2735 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/vk2735

> The next catalyst for VK2735, sponsored by Viking Therapeutics, Inc. (VKTX), is its primary completion, July 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | VK2735 |
| Codes | VK2735 |
| Sponsor | Viking Therapeutics, Inc. (VKTX) https://sec-api.dev/companies/vktx/catalysts |
| Indications | [obesity](https://sec-api.dev/indications/obesity), obesity, in june 2025, we, obesity, and in june 2025, we, [Weight Loss](https://sec-api.dev/indications/weight-loss) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2023: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: obesity.
- First seen 2025-02-26, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001193125-26-436432): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-401384): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312526401384/vktx-20260925.htm
- SEC prospectus (424B) (accession 0001193125-26-401385): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312526401385/vktx-20260925.htm
- SEC prospectus (424B) (accession 0001193125-26-399628): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312526399628/vktx-2026-09-23-424b5_co.htm
- SEC Form 10-Q (accession 0001193125-26-324219): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312526324219/vktx-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-193315): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312526193315/vktx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-046876): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm
- SEC Form 10-K (accession 0001193125-26-046876): "In September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-247059): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000119312525247059/vktx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-097950): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000095017025097950/vktx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-058129): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000095017025058129/vktx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-027824): "Based upon the results from this Phase 1 study, in September 2023, we initiated the VENTURE study, a Phase 2 clinical trial of VK2735 in patients with obesity." https://www.sec.gov/Archives/edgar/data/1607678/000095017025027824/vktx-20241231.htm

### Feb 2024: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 2. Indication: obesity, in June 2025, we.
- First seen 2025-02-26, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001193125-26-436432): "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, in June 2025, we announced the initiation of our VANQUISH Phase 3 program for the subcutaneous formulation." https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm
- SEC Form 10-Q (accession 0001193125-26-324219): "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, in June 2025, we announced the initiation of our VANQUISH Phase 3 program for the subcutaneous formulation and in August 2025, we announced positive top-line results from our Phase 2 clinical trial of the oral tablet formulation of VK2735." https://www.sec.gov/Archives/edgar/data/1607678/000119312526324219/vktx-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-193315): "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, in June 2025, we announced the initiation of our VANQUISH Phase 3 program for the subcutaneous formulation and in August 2025, we announced positive top-line results from our Phase 2 clinical trial of the oral tablet formulation of VK2735." https://www.sec.gov/Archives/edgar/data/1607678/000119312526193315/vktx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-046876): "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, in June 2025, we announced the initiation of our VANQUISH Phase 3 program for the subcutaneous formulation and in August 2025, we announced positive top-line results from our Phase 2 clinical trial of the oral tablet formulation of VK2735." https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm
- SEC Form 10-Q (accession 0001193125-25-247059): "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, in June 2025, we announced the initiation of our VANQUISH Phase 3 program for the subcutaneous formulation and in August 2025, we announced positive top-line results from our Phase 2 clinical trial of the oral tablet formulation of VK2735." https://www.sec.gov/Archives/edgar/data/1607678/000119312525247059/vktx-20250930.htm
- SEC Form 10-Q (accession 0000950170-25-097950): "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, and in June 2025, we announced the initiation of our VANQUISH Phase 3 program for the subcutaneous formulation." https://www.sec.gov/Archives/edgar/data/1607678/000095017025097950/vktx-20250630.htm
- SEC Form 10-Q (accession 0000950170-25-058129): "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, and we plan to advance the subcutaneous formulation of VK2735 into Phase 3 development." https://www.sec.gov/Archives/edgar/data/1607678/000095017025058129/vktx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-027824): "In February 2024, we reported positive top-line results from the VENTURE Phase 2 clinical trial for VK2735 in patients with obesity, and we plan to advance the subcutaneous formulation of VK2735 into Phase 3 development." https://www.sec.gov/Archives/edgar/data/1607678/000095017025027824/vktx-20241231.htm

### January 8, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2025-10-23, last confirmed 2026-10-29.
- SEC Form 10-Q (accession 0001193125-25-247059): "On January 8, 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and on August 19, 2025, we announced positive top-line results from the trial." https://www.sec.gov/Archives/edgar/data/1607678/000119312525247059/vktx-20250930.htm
- SEC Form 10-Q (accession 0001193125-26-436432): "In January 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and in August 2025, we announced positive top-line results from the trial." https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm
- SEC prospectus (424B) (accession 0001193125-26-401384): "In January 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and in August 2025, we announced positive top-line results from the trial." https://www.sec.gov/Archives/edgar/data/1607678/000119312526401384/vktx-20260925.htm
- SEC prospectus (424B) (accession 0001193125-26-401385): "In January 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and in August 2025, we announced positive top-line results from the trial." https://www.sec.gov/Archives/edgar/data/1607678/000119312526401385/vktx-20260925.htm
- SEC prospectus (424B) (accession 0001193125-26-399628): "In January 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and in August 2025, we announced positive top-line results from the trial." https://www.sec.gov/Archives/edgar/data/1607678/000119312526399628/vktx-2026-09-23-424b5_co.htm
- SEC Form 10-Q (accession 0001193125-26-324219): "In January 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and in August 2025, we announced positive top-line results from the trial." https://www.sec.gov/Archives/edgar/data/1607678/000119312526324219/vktx-20260630.htm
- SEC Form 10-Q (accession 0001193125-26-193315): "In January 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and in August 2025, we announced positive top-line results from the trial." https://www.sec.gov/Archives/edgar/data/1607678/000119312526193315/vktx-20260331.htm
- SEC Form 10-K (accession 0001193125-26-046876): "In January 2025, we announced the initiation of a Phase 2 clinical trial of the oral tablet formulation of VK2735, and in August 2025, we announced positive top-line results from the trial." https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm

### Q2 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-02-05, last confirmed 2025-04-24.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-014464): "Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25" https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/vktx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-014464): "Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25." https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/vktx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-014464): "The company expects to initiate Phase 3 trials evaluating subcutaneous VK2735 in obesity in 2Q25." https://www.sec.gov/Archives/edgar/data/1607678/000095017025014464/vktx-ex99_1.htm
- SEC Form 10-Q (accession 0000950170-25-058129): "Based on written feedback received from the U.S. Food and Drug Administration, or the FDA, we expect to initiate Phase 3 clinical studies of the subcutaneous formulation of VK2735 in the second quarter of 2025." https://www.sec.gov/Archives/edgar/data/1607678/000095017025058129/vktx-20250331.htm
- SEC Form 10-K (accession 0000950170-25-027824): "Based on written feedback received from the U.S. Food and Drug Administration, or the FDA, we expect to initiate Phase 3 clinical studies of the subcutaneous formulation of VK2735 in the first half of 2025." https://www.sec.gov/Archives/edgar/data/1607678/000095017025027824/vktx-20241231.htm

### June 24, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Weight Loss.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06828055 (VK2735 for Weight Management Phase 2 (Venture Oral Dosing)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Viking Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT06828055

### August 19, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 2.
- First seen 2025-07-23, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001607678-25-000003): "SAN DIEGO, CA - August 19, 2025 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's Phase 2 clinical trial of the oral tablet formulation of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors." https://www.sec.gov/Archives/edgar/data/1607678/000160767825000003/vktx-ex99_1.htm
- SEC Form 10-Q (accession 0001193125-26-436432): "In August 2025, we announced positive top-line results from our Phase 2 clinical trial of the oral tablet formulation of VK2735, and in October 2026, we announced the initiation of our SUNRISE Phase 3 clinical program for oral VK2735." https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm
- SEC Form 10-K (accession 0001193125-26-046876): "In August 2025, we announced positive top-line results from our Phase 2 VENTURE-Oral Dosing trial of the oral tablet formulation of VK2735." https://www.sec.gov/Archives/edgar/data/1607678/000119312526046876/vktx-20251231.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-097885): "Phase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25" https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/vktx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-097885): "Phase 2 VENTURE-Oral Dosing Trial Enrollment Completed; Top-Line Results Expected 2H25." https://www.sec.gov/Archives/edgar/data/1607678/000095017025097885/vktx-ex99_1.htm

### Oct 2025: trial start

- Status: completed. Date confidence: month. Stage: 1.
- First seen 2026-02-11, last confirmed 2026-07-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-323652): "In October 2025, Viking initiated a Phase 1 dose-ranging study designed to explore the feasibility of various VK2735 maintenance dosing regimens." https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-191487): "In October 2025, Viking initiated a Phase 1 study designed to explore the feasibility of various VK2735 maintenance dosing regimens." https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-046536): "In October 2025, Viking initiated a Phase 1 study designed to explore the feasibility of various VK2735 maintenance dosing regimens utilizing both the oral tablet and the subcutaneous formulation." https://www.sec.gov/Archives/edgar/data/1607678/000119312526046536/vktx-ex99_1.htm

### September 22, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2026-09-22, last confirmed 2026-10-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-397219): "SAN DIEGO, CA - September 22, 2026 - Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced positive top-line results from the company's maintenance study of VK2735, the company's dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors." https://www.sec.gov/Archives/edgar/data/1607678/000119312526397219/vktx-ex99_1.htm
- SEC prospectus (424B) (accession 0001193125-26-401384): "On September 22, 2026, we announced positive top-line results from our maintenance study of VK2735, our dual agonist of the GLP-1 and GIP receptors." https://www.sec.gov/Archives/edgar/data/1607678/000119312526401384/vktx-20260925.htm
- SEC prospectus (424B) (accession 0001193125-26-401385): "On September 22, 2026, we announced positive top-line results from our maintenance study of VK2735, our dual agonist of the GLP-1 and GIP receptors." https://www.sec.gov/Archives/edgar/data/1607678/000119312526401385/vktx-20260925.htm
- SEC prospectus (424B) (accession 0001193125-26-399628): "On September 22, 2026, we announced positive top-line results from our maintenance study of VK2735, our dual agonist of the GLP-1 and GIP receptors." https://www.sec.gov/Archives/edgar/data/1607678/000119312526399628/vktx-2026-09-23-424b5_co.htm
- SEC Form 10-Q (accession 0001193125-26-436432): "In September 2026, we announced positive top-line results from the first part of the study." https://www.sec.gov/Archives/edgar/data/1607678/000119312526436432/vktx-20260930.htm

### Q4 2026: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2026-04-29, last confirmed 2026-07-29.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-191487): "-- Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26 --" https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-191487): "Initiation of Phase 3 Oral VK2735 Trial for Obesity Expected 4Q26." https://www.sec.gov/Archives/edgar/data/1607678/000119312526191487/vktx-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-323652): "During the period, the company continued to prepare for initiation of Phase 3 trials with the oral formulation of VK2735, expected to begin in the fourth quarter of this year." https://www.sec.gov/Archives/edgar/data/1607678/000119312526323652/vktx-ex99_1.htm

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Weight Loss.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07104383

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Weight Loss.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07104383 (VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07104383

### July 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Weight Loss.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07104500 (VK2735 for Weight Management Phase 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07104500

### Jul to Oct 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Weight Loss.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07104500 (VK2735 for Weight Management Phase 3): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-01 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07104500

### July 2028: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Weight Loss.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07868835 (Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07868835

### Jul to Oct 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Weight Loss.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07868835 (Oral VK2735 for Weight Management Phase 3 (SUNRISE 1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-07 (ESTIMATED); Lead Sponsor Viking Therapeutics, Inc.." https://clinicaltrials.gov/study/NCT07868835

## Same indication

- [ISEMBYLD (apitegromab)](https://sec-api.dev/pdufa/apitegromab) (SRRK)
- [CRB-913](https://sec-api.dev/pdufa/crb-913) (CRBP)
- [DA-1726](https://sec-api.dev/pdufa/da-1726) (MTVA)
- [RT-114](https://sec-api.dev/pdufa/rt-114) (RANI)
- [RaniPill (RT-116)](https://sec-api.dev/pdufa/rt-116) (RANI)
- [Wegovy (semaglutide)](https://sec-api.dev/pdufa/semaglutide) (NVO)
- [Vk2735 oral](https://sec-api.dev/pdufa/vk2735-oral) (VKTX)
- [WVE-007](https://sec-api.dev/pdufa/wve-007) (WVE)

Calendar months: [July 2027](https://sec-api.dev/fda-calendar/2027-07)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/vk2735.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "VK2735 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/vk2735

```bibtex
@misc{secapidev_pdufa_vk2735_20261116,
  title        = {VK2735 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/vk2735}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_vk2735_20261116","title":"VK2735 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/vk2735","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
